These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 32990939)

  • 1. Atezolizumab: A Review in Extensive-Stage SCLC.
    Frampton JE
    Drugs; 2020 Oct; 80(15):1587-1594. PubMed ID: 32990939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
    Liu SV; Reck M; Mansfield AS; Mok T; Scherpereel A; Reinmuth N; Garassino MC; De Castro Carpeno J; Califano R; Nishio M; Orlandi F; Alatorre-Alexander J; Leal T; Cheng Y; Lee JS; Lam S; McCleland M; Deng Y; Phan S; Horn L
    J Clin Oncol; 2021 Feb; 39(6):619-630. PubMed ID: 33439693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.
    Mansfield AS; Każarnowicz A; Karaseva N; Sánchez A; De Boer R; Andric Z; Reck M; Atagi S; Lee JS; Garassino M; Liu SV; Horn L; Wen X; Quach C; Yu W; Kabbinavar F; Lam S; Morris S; Califano R
    Ann Oncol; 2020 Feb; 31(2):310-317. PubMed ID: 31959349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study.
    Reck M; Dziadziuszko R; Sugawara S; Kao S; Hochmair M; Huemer F; de Castro G; Havel L; Bernabé Caro R; Losonczy G; Lee JS; Kowalski DM; Andric Z; Califano R; Veatch A; Gerstner G; Batus M; Morris S; Kaul M; Cuchelkar V; Li H; Danner BJ; Nabet BY; Liu SV
    Lung Cancer; 2024 Oct; 196():107924. PubMed ID: 39306923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
    Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Hoshino T
    Invest New Drugs; 2021 Feb; 39(1):269-271. PubMed ID: 32783090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
    Horn L; Mansfield AS; Szczęsna A; Havel L; Krzakowski M; Hochmair MJ; Huemer F; Losonczy G; Johnson ML; Nishio M; Reck M; Mok T; Lam S; Shames DS; Liu J; Ding B; Lopez-Chavez A; Kabbinavar F; Lin W; Sandler A; Liu SV;
    N Engl J Med; 2018 Dec; 379(23):2220-2229. PubMed ID: 30280641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Real-world Efficacy and Safety of Atezolizumab and Durvalumab in Combination With Chemotherapy for First-line Treatment of Extensive-stage Small-cell Lung Cancer.
    Igata F; Inoue H; Ikeda T; Nakao A; Ebi N; Fujita M
    Anticancer Res; 2024 Jul; 44(7):3175-3183. PubMed ID: 38925816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
    Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
    Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy.
    Ilhan Y; Ucar G; Baser MN; Guzel HG; Efil SC; Demir B; Ercan Uzundal D; Karacelik T; Sever N; Balcik OY; Arvas H; Karadag I; Kadioglu A; Ekinci ÖB; Karacin C; Urakci Z; Kostek O; Karakurt Eryilmaz M; Yazici O; Sendur MAN; Ozturk B; Uncu D; Ergun Y
    Expert Opin Pharmacother; 2024 Aug; 25(11):1555-1563. PubMed ID: 39115275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.
    Reck M; Mok TSK; Mansfield A; De Boer R; Losonczy G; Sugawara S; Dziadziuszko R; Krzakowski M; Smolin A; Hochmair M; Garassino MC; de Castro Junior G; Bischoff H; Lam S; Cardona A; Morris S; Liu SV
    J Thorac Oncol; 2022 Sep; 17(9):1122-1129. PubMed ID: 35764236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial.
    Bria E; Morgillo F; Garassino MC; Ciardiello F; Ardizzoni A; Stefani A; Verderame F; Morabito A; Chella A; Tonini G; Gilli M; Del Signore E; Berardi R; Mencoboni M; Bearz A; Delmonte A; Migliorino MR; Gridelli C; Pazzola A; Iero M; De Marinis F
    Oncologist; 2024 May; 29(5):e690-e698. PubMed ID: 38377176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab: A Review in Extensive-Stage SCLC.
    Al-Salama ZT
    Target Oncol; 2021 Nov; 16(6):857-864. PubMed ID: 34731446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide.
    Liu SV; Mok TSK; Nabet BY; Mansfield AS; De Boer R; Losonczy G; Sugawara S; Dziadziuszko R; Krzakowski M; Smolin A; Hochmair MJ; Garassino MC; Gay CM; Heymach JV; Byers LA; Lam S; Cardona A; Morris S; Adler L; Shames DS; Reck M
    Lung Cancer; 2023 Dec; 186():107418. PubMed ID: 37931445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
    Mathieu L; Shah S; Pai-Scherf L; Larkins E; Vallejo J; Li X; Rodriguez L; Mishra-Kalyani P; Goldberg KB; Kluetz PG; Theoret MR; Beaver JA; Pazdur R; Singh H
    Oncologist; 2021 May; 26(5):433-438. PubMed ID: 33687763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer.
    Kataoka N; Kunimatsu Y; Tachibana Y; Sugimoto T; Sato I; Tani N; Ogura Y; Hirose K; Takeda T
    Thorac Cancer; 2020 Sep; 11(9):2740-2742. PubMed ID: 32706170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133).
    Nishio M; Sugawara S; Atagi S; Akamatsu H; Sakai H; Okamoto I; Takayama K; Hayashi H; Nakagawa Y; Kawakami T
    Clin Lung Cancer; 2019 Nov; 20(6):469-476.e1. PubMed ID: 31466854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
    Zhou K; Zhou J; Huang J; Zhang N; Bai L; Yang Y; Li Q
    Lung Cancer; 2019 Apr; 130():1-4. PubMed ID: 30885327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.
    Andrini E; Lamberti G; Mazzoni F; Riccardi F; Bonetti A; Follador A; Artioli F; Genova C; Barbieri F; Frassoldati A; Brighenti M; Colantonio I; Pasello G; Ficorella C; Cinieri S; Tiseo M; Gelsomino F; Tognetto M; Rihawi K; Ardizzoni A
    Future Oncol; 2022 Mar; 18(7):771-779. PubMed ID: 35068173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
    Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
    JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.